Index

Abacavir, 403
Absorption, drug, 387, 388
Abuse, see Alcohol abuse; Drugs of abuse
Acenocoumarol
analysis of, 175
electrospray mass spectra of, 176
ion chromatograms, 177
Acetaldehyde toxicity, 124
Acetaminophen
chemical structure of, 2, 3
interaction with warfarin of, 167
interference of high bilirubin in colorimetric assay for, 228
toxicity, 423
and warfarin therapy, 166
Acetaminophen assays, 2
chromatographic methods, 4–5
commercially available, 4
false-positive, 5–6
interferences with, 5
Acetoacetate, and false-positive salicylate assay, 55
Acetylcholinesterase activity, in carbamate poisoning, 146–147
Aconite-containing Chinese herbs, fatality associated with, 187
Aconite poisoning, chromatographic analysis for, 201–202
Acquired immunodeficiency syndrome (AIDS), monitoring anticonvulsants in, 281–282, See also AIDS patients
Acute lymphoblastic leukemia (ALL), therapeutic drug monitoring in, 8
Adderall
amphetamine excretion profile for, 68
positive amphetamine results with, 69
Adolescents
alcohol as risk factor for, 2
plant poisoning of, 186
AdultaCheck 4, 46

© 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.
Adulterants, See also specific adulterants
dipstick testing for, 46
guidelines for detecting, 46
in vitro urinary, 41–46
Adulteration, of herbal remedies, 418–419
Adverse drug reactions, and TDM, 386, 387
ADVIA 1650 analyzr, turbidimetric assay on, 257
ADVIA Centaur assay, 338
for carbamazepine, 272–273
major interferences in, 344
Agriculture, pesticide use in, 140
AIDS patients
carbamazepine toxicity in, 284–285
and drug-herb interactions, 359
herbal supplement use of, 357, 357
monitoring anticonvulsants in, 281–282
St. John’s wort used by, 364
Alcohol, 135
benefits of consuming moderate, 125, 125–126
binge drinking, 125
hazardous drinking, 124–125
health benefits of, 121, 125, 135
heavy consumption of, 125
hospital admission statistics for, 1
and legal limit for driving, 126–127
metabolism of, 122–125
standard drink, 121–122
and warfarin therapy, 166–167
Alcohol abuse, See also Blood alcohol analysis
denied by patient with positive results, 416
moderate drinking vs., 125, 125–126
Alcohol analysis, See also Blood alcohol analysis
alternative method for, 418
methods, 6
Alcohol biomarkers, false-positive, 418
Alcohol dehydrogenase (ADH), 123, 135
Alcoholic beverages, classification of, 121
Alcotest Models, 130
Alkaloids
aphedrine, 200
ephedrine, 200
hepatotoxicity associated with, 195, 196, 197
steroidal, 188
toxicity of, 188
Alleles (genetic polymorphisms), 389–390
Allopurinol, hypersensitivity to, 403
Alprazolam, interactions of St. John’s wort with, 366, See also Benzodiazepines
Amanita mushrooms, 102
American College of Cardiology/ American Heart Association,
digoxin guidelines of, 238
Amino acids, potential toxicity of, 190
Aminoglycosides, therapeutic monitoring of, 223, 386
Amiodarone
and digoxin toxicity, 238
interaction with digoxin of, 243, 244
interaction with warfarin of, 166, 167
interference with digoxin immunoassay of, 244
Amitriptyline
chemical structure of, 294
effectiveness of, 296
interaction of St. John’s wort with, 372
pharmacogenomics of, 401
therapeutic monitoring of, 300
therapeutic range for, 293, 294
Amoxapine
therapeutic monitoring of, 314
therapeutic range for, 315
Amphetamine abuse, 53
Amphetamine immunoassay(s), 54
classification of, 54
cross-reactivities of MDMA and MDA with, 55, 55
drugs interfering with, 57
interferences in, 54
dietary weight loss products, 59
sympathomimetic amines, 55–57, 57
Vicks inhaler, 57–59
ma huang false-positive response in, 200
Amphetamines, testing for, 22–23
Amphetamine test results
drugs causing positive, 69, 69
positive, 67–70, 69
Amphetamine-type designer drugs, 86, 87, 88, 89–90
classification of, 86, 88
metabolism of, 89–90
toxicity of, 90–91
AmpliChip CYP450 test, 403, 404
Anesthetics, 21
Angel’s trumpet (Datura swaveolens), 104, 186
diagnosis of poisoning with, 203
toxicity of, 187
Anion gap
defined, 150
in methanol and ethylene glycol poisoning, 157
Antiasthmatic drugs, therapeutic monitoring of, 10
Antibiotics, See also specific antibodies
interaction of St. John’s wort with, 372
interaction with warfarin of, 165, 167
therapeutic monitoring of, 10
Antibody conjugated magnetic
immunoassay (ACMIA), 335, 335
for cyclosporine, 338–339
major interferences in, 344
for tacrolimus, 340, 341
Anticancer drugs
interaction of St. John’s wort with, 365–366, 372
pharmacogenomics and, 396–397
therapeutic monitoring of, 397
Anticholinergic syndrome, with plant poisoning, 203
Anticoagulants, See also Warfarin therapy
coumarin-type, 161
determination of coumarin-type, 175–178, 176, 177
heparin, 214–215
interaction of St. John’s wort with, 372
pharmacogenomic testing of, 395
Anticonvulsants
classical, 286
and drug-drug interactions, 282–283
monitoring free concentrations of, 276, 276–278, 279–281
in AIDS patients, 281–282
in liver disease, 278
in uremic patients, 278
newer, 266
during pregnancy, 281
therapeutic monitoring of, 8–9, 10, 11
265, 266, 267
newer anticonvulsants, 285–286
phenytoin toxicity, 283–284
Antidepressants, See also Tricyclic antidepressants
interactions of St. John’s wort with, 366–367
interaction with warfarin of, 166, 167
pharmacogenomic testing of, 395
specimen collection for, 221
suicide attempts involving, 301
therapeutic monitoring of, 10, 11
Antidepressants, newer, 316–317, 401
chromatographic methods for monitoring, 315–316
therapeutic monitoring of, 314–316, 315, 401
therapeutic ranges for, 315, 315
Antidiabetics, interaction of St. John’s wort with, 372
Antidotes, for treating plant poisoning, 191
Antiepileptic drugs
gender differences in disposition of, 11–12
interaction with ginkgo biloba of, 374
and St. John’s wort, 368
Antifungals
interaction of St. John’s wort with interaction with warfarin of, 166, 167
Antihistamines, interference with TCA immunoassays of, 302, 310–312
Antihyperlipidemic agents, interaction of St. John’s wort with, 368
Antimetabolite/proliferative agents, 324
Antineoplastic drugs, See also Anticancer drugs
pharmacogenomic testing of, 395
and St. John’s wort, 360
Antiretroviral drugs
and pharmacogenomics, 400
therapeutic monitoring of, 11, 400
Anxiety disorders, treatment of, 295–296
Architect ci8200 analyzer, 417
Architect immunoassay
for immunosuppressants, 338
for tacrolimus, 339
ARCHITECT immunoassay platforms,
255
ARCHITECT clinical chemistry platforms,
255
Ascorbic acid (vitamin C), as adulterant,
42, 43
Aspirin, See also Salicylate assays;
Salicylate poisoning
interaction with warfarin of, 165
and warfarin therapy, 168
Atherogenesis, and alcohol consumption,
126
Atorvastatin, interaction of St. John’s
wort with, 368
Attention deficit disorder (ADD),
amphetamine and
methamphetamine for, 68
Australia, herbal supplements in, 356
AxSYM platform, interferences of
Chinese medicine in, 256
Barbiturates
interaction with warfarin of, 167
testing for, 25
Barrier gel
absorption of phenytoin by, 221
in serum separator tubes, 218–222,
219
Beckman assay
interferences of Chinese medicine in, 256
interference with oleander in, 257
Becton-Dickinson SST tubes, 219, 219,
220–222
Beer consumption, and warfarin therapy,
166–167
Benzodiazepines, See also specific
benzodiazepines
commonly used, 76, 77
immunoassay screening for, 76–77
interaction of St. John’s wort with, 366,
372
interference with immunoassays of, 62,
62
On-Line Benzodiazepine Plus assay,
77
positive testing results with, 77–78
testing for, 25
uses for, 76
Benzodiazepine test results, true-positive,
76–78, 77
Benzoylecgonine
positive tests results with, 78–79
screening and confirmation cut-offs
for, 36
testing, 23
β-human chorionic gonadotropin
(β-hCG), 249–250
β-human chorionic gonadotropin
(β-hCG) assay, false-negative
result in, 425
β-lactam antibiotics, therapeutic
monitoring of, 386–387
Bezoars, in delayed toxicity, 3
Bilirubin, See also Hyperbilirubinemia
false-positive acetaminophen test
results with, 5
interference in therapeutic drug
monitoring of, 227–230
Bitter orange, 200
Bleach, laundry, as adulterant, 41, 43
Blood alcohol analysis, 1
determination of, 126–127
breath alcohol vs., 128–132
methods, 132–135, 134
Widmark formula, 127–128
false-positive results, viii
Blood clotting factors, 161
Blood collection, correct order of draw
for, 225–226, See also Specimen
collection; Whole blood
Breathalyzer, operation of, 129
Breath analyzer(s), 130–131
chemical principle of, 129–131
and interferences in measuring
alcohol, 131–132
interference with, 135
and methanol poisoning, 132
Breynia officinalis (Chi R Yun), 196, 197
Brodifacoum, 174, 179
Bromadiolone, determination of, 179
Bufalin
chemical structure of, 254, 255
interference with digoxin assays of,
256
Bupropion
interference with amphetamine
immunoassays of, 60
therapeutic monitoring of, 314
Buspirone, interactions of St. John’s wort with, 366, 367
Butyrylcholinesterase, enzymatic activity of, 395
Butyrylcholinesterase, in insecticide poisoning, 145–146
Cactus, peyote, see Peyote cactus
Calcineurin inhibitors, mechanism of action of, 324–325
Calcium channel blockers, interaction with St. John’s wort of, 365
Canada, herbal supplements in, 356
Cancer patients, herbal supplement use of, 357, 357
Cannabinoids, 21
and false-positive results, 62
synthetic, 96
Cannabis, hospital admission statistics for, 1–2
Canrenone, interference with digoxin immunoassays of, 253–256
Caowu, 202
Carbamate poisoning, 143
case reports, 145
cholinesterase in diagnosis of, 145–147
clinical features of, 144
inhibition of acetylcholinesterase in, 146
treatment for, 144
Carbamates, 140, 144
Carbamazepine
chemical structure of, 268, 303
free fraction for, 278
free level of, 420–421
interaction with warfarin of, 166, 167
interference with TCA immunoassays of, 302, 306–308
monitoring free drug concentrations for, 286
during pregnancy, 281
and Stevens-Johnson syndrome, 402–403
therapeutic monitoring of, 265, 286
therapeutic range for, 276
toxicity of, 421
in AIDS patients, 284–385
case study, 307
induced by protease inhibitors, 284
Carbamazepine epoxide
chemical structure of, 271
cross-reactivity of, 272, 272
determination of, 273
Carbamazepine immunoassays, interferences in, 266, 267, 270–275, 271, 272
3-carboxy-4-methyl-5-propyl-2-furanpropioniate (CMPF), 278
Cardenolides, from yellow oleander, 256
Cardiac panel, in plant poisoning or toxicity, 191
Cardioactive drugs
interaction of St. John’s wort with, 365, 372
narrow therapeutic ranges for, 399–400
and pharmacogenomics, 399–400
pharmacogenomic testing of, 395
therapeutic monitoring of, 10, 11
Cardiovascular disease
and drug disposition, 15
and heavy alcohol drinking, 126
Castor beans (Ricinus communis), 186, 187
diagnosis of poisoning with, 202–203
toxicity of, 187
Catheine, 110
Cathinone, 110
chemical structure of, 112
concentrations in khat, 112
detection of, 113
“Cat” (methcathinone), 112
Cedar, red or white (Thuja), 186
Central lines, drawing specimens from, 226
Central nervous system depressants, 21
Cetirizine, 274
chemical structure of, 303
interference with TCA immunoassays of, 302, 310–311
Chan Su
and Digibind therapy, 194–195
digoxin immunoassay for identifying, 192, 192
Chan Su (cont’d)
  eliminating interferences caused by, 258
  fatality associated with, 187
  interference with digoxin assays of, 255–256
  toxicity of, 206
Chaparral (Larrea tridentata)
  hepatotoxicity of, 195, 196, 196, 206
  medical uses for, 196
Chemicals, household
  as adulterants, 41–42, 43
  volatiles and inhalants, 114, 115
Chemiluminescent assay, 257
Chemiluminescent immunoassay, phenytoin determination with, 267
Chemiluminescent microparticle immunoassay (CMIA)
  of immunosuppressants, 335, 336, 337–338
  major interferences in, 344
    for sirolimus, 342
    for tacrolimus, 340
Chemotherapy, 396, See also Anticancer drugs
Children
  altered pharmacokinetics in, 15–16
  and drug-herb interactions, 359
  plant poisoning in, 185, 186
China, herbal supplement use in, 356
China White, abuse of, 92–93
Chinese medicines, interference with digoxin immunoassays of, 246
Chiral analysis, of methamphetamine, 58–59
Chi R Yun (Breynia officinalis), 196, 197
Chlorinated solvents, chronic abuse of, 114
Chlorophacinone, 174
P-chlorowarfarin (coumachlor)
  electrospray mass spectra of, 176
  as internal standard, 177
  ion chromatograms of, 177
Chlorpromazine, chemical structure of, 303
Chlorpyrifos
  chemical structure of, 142
  poisoning, 142
Cholestatic disease states, 388
Cholesterol-lowering drugs, interaction of St. John’s wort with, 372
Cholinesterases, human, 143
Cholinesterase test
  as diagnostic, 145–147
  for pesticide poisonings, 139
Chromatographic analysis
  of aconite poisoning, 201–202
  of angel’s trumpet poisoning, 203
  availability of, 206
  of ricin, 202–203
  of weight loss products, 199–201
Chromatographic methods, See also Gas chromatography; Liquid chromatography
  for TDM of newer anticonvulsants, 285–286
  for TDM of TCAs, 301, 312–314, 317
  for therapeutic drug monitoring, 19–20
  for therapeutic drug monitoring of immunosuppressants, 347
  for warfarin, 174–178, 176, 177
Chromatography
  of superwarfarin compounds, 178–179
  of TDM of immunosuppressants, 343, 345–347
Chromium, and antidiabetic medication, 378
Chronically ill
  complementary and alternative medicine (CAM) used by, 357, 357
  herbal supplements used by, 357, 357–358
Chuanwu, 202
Chylomicrons, 230–231
Cimetidine, interaction with warfarin of, 167
Citalopram, therapeutic range for, 315
Clarithromycin, interaction with digoxin of, 243–244
Clinical Laboratory Improvement Act (CLIA) (1988), 403
Clinical Laboratory Standards Institute, 227
Clofibrate, interaction with warfarin of, 167
Clomipramine, therapeutic range for, 293, 294
Cloned enzyme donor immunoassay (CEDIA), 37
for amphetamine, 201
of carbamazepine, 274
of digoxin, 249
of immunosuppressants, 335, 336
major interferences in, 344
for mycophenolic acid, 267
for sirolimus, 341
for tacrolimus, 339
Clopidogrel
interaction with warfarin of, 167
pharmacogenomics of, 400
Clovers, 189
Club drugs, detection of, 37, 97, See also Designer drugs
C2 monitoring, 329
Coagulant, for serum specimens, 214
Cobas Integra analyzer, 60–61
COBAS INTEGRA systems, 336
Cocaine
positive test results with, 78–80
in postmortem samples, 80
Cocaine metabolite benzoylecgonine, testing for, 23, See also Benzoylecgonine
Coca tea, 78
Codeine
positive confirmation of, 36
positive opiate test results with, 72
positive test results for, 74
Cold and cough medication, positive amphetamine/methamphetamine test results with, 67–68
Collection tubes, See also Serum separator tubes
appropriate, 216, 216–218
for tetrahydrocannabinol (THC) analysis, 217
College of American Pathologists, 21
Coltsfoot
fatality associated with, 187
hepatotoxicity associated with, 195
Comfrey, fatality associated with, 187
Complementary and alternative medicine (CAM), 255
AIDS patients’ use of, 357, 357
in chronic illness, 357, 357
Contact dermatitis, oxalate-caused, 189
Contraceptives, interaction with antiepileptic drugs of, 12
Controlled Substances Act, U.S., 1986 amendment of, 85
Corticosteroids, 324
Corvac tubes, 219, 219, 220
Coumachlor (p-chlorowarfarin), 176, 177, 177
Coumarin plant, 189
Cranberry juice, interaction with warfarin of, 170–171
Creatinine kinase (CK) reagent, 417
Critically ill, free anticonvulsant concentrations in, 279
Cut-off concentrations, in drug testing, 35–37
Cyanogenic glycosides, 188–189
Cyclobenzaprine
chemical structure of, 303
interference with TCA immunoassay of, 302, 312
Cyclosporine
chemical structure of, 326, 327
commercially available immunoassays for, 335
dosing for, 324
drug interactions with, 324
FPIA of, 214
interaction with St. John’s wort of, 562–563
limitations of immunoassays for, 337–339
major interferences in immunoassays of, 344
mechanism of action of, 324–325
pharmacokinetics of, 329–330
therapeutic monitoring of, 326, 329–330
T lymphocytes targeted by, 323
toxicity of, 325
Cyclosporine measurement, collection tubes for, 217
CYP3A4  
oral contraceptives metabolized by, 369  
in St. John’s wort metabolism, 360–361  
CYP2C9, 163, 164  
CYP2D6, and pharmacokinetics, 385–386  
Cyproheptadine  
chemical structure of, 304  
interference with TCA immunoassay of, 302, 308–309  
Cytochrome P450 enzymes, 123  
cyclosporine metabolized by, 326  
and drug metabolism, 387  
and psychoactive drugs, 401  
Cytochrome P450 isoenzymes, in  
metabolism of TCAs, 298–299  
Cytochrome P450 proteins (CYPs), 390–390  

Danshen, and Digibind therapy, 194–195  
Data Master cdm, 130  
Deadly nightshade (Atropa belladonna), 186  
Denture cleaning tablets, as adulterants, 42, 43  
Depressed patients, and drug-herb interactions, 359  
Designer drugs  
abuse of, 54  
amphetamine-type, 86, 87, 88, 89–90  
analogs for, 86, 86  
commonly abused, 85, 86  
detection of, 26, 97  
examples of, 89  
fentanyl analogs, 92–93  
GHB, 94  
liquid, 89  
marijuana analogs as, 96–97  
meperidine analogs, 93  
opoid, 91–93  
phencyclidine analogs, 93–94  
related to phenethylamine, 91  
street names for, 86, 86  
testing for, 37, 38  
Desipramine  
chemical structure of, 294  
therapeutic monitoring of, 300  
therapeutic range for, 293, 294  
Detection, window of, 22  

Detergent, as adulterant, 42, 43  
Detoxifying agents, for adulterating drug specimens, 40–41  
Dextromethorphan, and false-positive results, 61  
Diabetic patients, and drug-herb interactions, 359  
Diazepam, hospital admission statistics for, 1–2  
Dichloodiphenyl trichloroethane (DDT), 140  

Dietary Supplement Health and Education Act (1994), 187, 255, 355  
Digibind, 194, 206, 412  
for digoxin overdose, 251  
effect on DLIS, 248  
interference with serum digoxin measurement of, 252  
molecular weight of, 252  
for oleander poisoning, 192–193  
treatment with, 425  
Digibind/DigiFab, interference with  
digoxin immunoassays of, 247  
DigiFab  
for digoxin overdose, 251  
termination with serum digoxin measurement of, 252  
molecular weight of, 252  
preparation of, 251–252  

Digoxin  
bioavailability of, 238  
chemical structure of, 254, 255  
interaction of St. John’s wort with, 365, 372  
mechanism of action of, 239  
pharmacogenomics of, 400  
safety of, 237  
specimens for measurement of, 223  
therapeutic monitoring of, 8, 239–240  
analytical methods for, 245–246  
controversies in, 240–242, 242  
and digoxin-drug interaction, 242, 243–245  
indication for, 240, 240  
therapeutic range for, 238, 241, 244  
toxicity of, 241–242, 242
Digoxin immunoassays, 245–246, 247
effect of endogenous factors on,
246–247, 247
DLIS, 247, 247–249
heterophilic antibody, 249–250
effect of exogenous factors on, 250
Chinese medicines, 247, 255–257
Digibind and DigiFab, 251–253
digoxin metabolites, 250–251
herbal supplements, 247, 255–257
potassium-sparing diuretics, 247,
253–255, 254
eliminating interferences in, 257–258,
258
interferences with, 246, 257
oleander plant poisoning detected by,
192
in plant poisoning or toxicity, 191
Digoxin-like immunoreactive substances
(DLIS), 246, 247, 257
eliminating interferences caused by,
258
interferences with serum digoxin
measurement of, 248–249
measurement of, 247–248
Digoxin toxicity
case studies, 243–244, 252–253
factors increasing risk of, 242
and negative interference, vii
symptoms of, 253
Dimension analyzer, 424
2,5-dimethoxy-4-methylamphetamine
(DOM), 89
2,5-dimethoxy-4-methylthioamphetamine
(DOT), 89
Dioxin III assay on AXSYM platform,
257
Diphenhydramine
chemical structure of, 303
interference with immunoassays of,
63
interference with TCA immunoassays
of, 302, 311–312
Dipstick testing, for adulteration of
specimens, 46
Discordant specimen/interference
clinical investigation of
with alcohol use denied but test
results positive, 416–418
drug abuse denied with positive
results, 416
overdosed patient with negative
toxicology report, 414–416, 415
with discontinued medication, 421
drug level not matching clinical
condition, 421–423
high drug level without symptoms, 421
identifying, 412
probable causes for, 414, 415
resolving analytical interferences,
424–426, 425
subtherapeutic drug level with
compliant patient, 419–420
toxicity in therapeutic range, 420–421
unexpected levels, 420
when medication use denied, 418–419
Discordant specimens
investigating, 412–414
recognizing, 426
Distribution, drug, 387, 388
Diuretics, interaction of digoxin with,
245
Diuretics, potassium-sparing,
interference with digoxin
immunoassays of, 247, 253–255,
254
Doxepin
chemical structure of, 294
therapeutic range for, 293, 294
Doxorubicin, pharmacogenomics of, 396
Drager Evidentiary portable breath
alcohol analyzer, 131
DRI oxycodone assay, 24
Drug abuse, denied with positive results,
416
Drug administration, and therapeutic
monitoring, 7
Drug concentrations, and clinical
efficacy, 387
Drug disposition, gender differences in,
9, 11–13, 12
Drug-drug interactions
and elevated free anticonvulsant
concentrations, 282–283
of immunosuppressive agents, 342
and risk of digoxin toxicity, 242, 242,
243–245
and subtherapeutic drug level, 419–420
Drug-herb interactions, 373, 376–377
common, 373
with garlic, 373, 374–375
with ginkgo biloba, 373, 373–374
 Ginsengs, 371
importance of, 356–358, 357
with kava, 373, 375–376
not routinely monitored, 378
patients susceptible to adverse, 358, 359
patients vulnerable to, 358, 359
potential life-threatening, 378–379
potentially clinically significant, 358
risks of, 378
and role of laboratory, 377–378
with St. John’s wort, 358–371, 359, 362, 372
and therapeutic drug monitoring, 358
and unexpected test results, 412
with valerian, 373, 375–376
of various immunosuppressants, 324
Drug information compendiums, 168
Drug metabolites, measurement of, 394–395
Drugs of abuse
adulteration of specimens, 39–40, 40
flushing and detoxifying agents, 40–41
with glutaraldehyde, 45
guidelines for detecting, 46
house chemicals for, 41–42, 43
integrity test for, 43
with nitrite, 44
with Stealth, 44–45
Urine Luck, 43
classification of, 21
immunoassays of
false-positive results with, 61
for initial screening, 26
testing, 21–22, 31
for amphetamines, 22–23
for barbiturates and benzodiazepines, 25
changing results, 40, 40
for cocaine metabolite benzoylecgonine, 23
cut-off concentrations for, 33, 33, 35–37
detection window for, 34, 34
erroneous results in, 411
false-positive test results in, 63
for marijuana metabolite, 23
methods used, 25–26
for opiates, 23–24
for phenylcaine, 24–25
positive results, 67
undetected drugs, 37–39, 38
Drug testing. See also Workplace drug testing; specific tests
in alternative specimens, 47–48
within construction industry, 33
Drug testing panel, SAMHSA-mandated, 80
Drug toxicity, and SNPs, 385
Duragesic patches, of fentanyl, 92
DWI (driving with impairment), 126
Echinacea, interaction with drugs of, 373, 376–377
Ecstasy, see 3,4-methylenedioxymethamphetamine
Elderly
alcohol consumption for, 124
altered pharmacokinetics in, 15–16
anticonvulsants in, 281
and drug-herb interactions, 359
and risk of digoxin toxicity, 242, 242
SSRIs used by, 314
susceptibility to drug toxicity of, 9
of treatment of depression in, 295
Elecsys analyzer, 417
Electrochemical detection technique, 19
Electrolyte imbalance, and risk of
digoxin toxicity, 242, 242
Electronic health records, 413–414
Electron ionization (EI), 20
Elimination, drug, 388
Emagreese Sim, 59
Enzyme-linked immunoassay (EIA),
analytic performance criteria for, 36–37
Enzyme-multiplied immunoassay technique (EMIT), 5
analytic performance criteria for, 36–37
digoxin measurements with, 254
of immunosuppressants, 335, 336
major interferences in, 344
for mycophenolic acid, 342
phenytoin determination with, 267, 269
for tacrolimus, 339
for TCAs, 308, 309
tobramycin determination by, 215
Enzymes, See also specific enzymes
drug-metabolizing, 388, 389
G6PD, 392–393
impact of genetic variations on, 389
Ephedra (Ma Huang), chromatographic analysis of, 199, 199–201
Ephedrine
false-positive test results with, 56–57
mass spectral fragmentation pattern for, 56, 57
misidentification of, 56
EP7-P protocol, of National Committee for Clinical Laboratory Standardization, 227
Ergot, 188
Erythromycin
interaction of St. John’s wort with, 372
interaction with digoxin of, 243
Essential oils, of plant origins, 190
Ethyl alcohol, analysis of, 132–133, See also Alcohol
Ethylene glycol
metabolism of, 152–153
properties of, 152
skin absorption of, 152
toxicity of, 153
Ethylene glycol poisoning, 139
acute renal failure in, 153–154
case report, 154–155
laboratory diagnosis of, 154, 155
treatment for, 156
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), 24
2-ethyl-5-methyl-3,3-diphenylpyrrolidine (EMDP), 24
Ethylmorphine, positive test results with, 73
European market, herbal supplements in, 356
Everolimus
adverse effects of, 333
chemical structure of, 328
immunoassays for commercially available, 335
limitations of, 342
major interferences in, 344
mechanism of action of, 325
metabolism of, 32–333
therapeutic monitoring of, 332–333
Excretion, drug, 387
Extensive metabolizers (EMs), 390, 394
False-negative results, vii
with immunoassays, 26
resolution of, 413
False-positive results, vii
in amphetamine immunoassays, 55–56, 60
avoidance of, 63
and GC/MS confirmation, 63
with immunoassays, 26
with opiate immunoassay screening, 60
resolution of, 413
Famprofazone, false-positive test results with, 69
Farming, and pesticide exposure, 140
Federal Workplace Drug Testing Programs, Mandatory Guidelines for, 32, See also Workplace drug testing
Fenproporex, 59
Fentanyl
abuse of, 92
detection of, 93
testing for, 24
Fentanyl analogs, as designer drugs, 92–93
Fentanyl-containing drugs, 72
FK-506, see Tacrolimus
Flame ionization detector (FID), for analysis of TCAs, 313
Flatliners, 89
Flecainide, and digoxin toxicity, 238
Flocoumafen, determination of, 179
Fluconazole, interaction with warfarin of, 166, 167
Flunitrazepam (Rohypnol)
chemical structure of, 87
detection of, 37
Fluorescence polarization immunoassay (FPIA)
for amphetamine/methamphetamine analysis, 58
analytic performance criteria for, 36–37
bilirubin interference in, 229
of cyclosporine, 214
for determination of phenytoin, 267
digoxin assay with, 193, 194, 254, 257
and DLIS, 248
for everolimus, 342
and mebeverine metabolism, 68
phenytoin determination with, 267
psilocin detection with, 105
for TCAs, 305, 306, 311, 312
Fluorescence technique, 19

Fluoroquinolone antibiotics, interference with opiate immunoassays of, 60

Fluoxetine
chemical structure of, 295, 295
therapeutic range for, 315

Flushing and detoxifying agents, for adulterating drug specimens, 40–41

Fluvaxamine, therapeutic range for, 315

Food and Drug Administration (FDA)
GHB over-the-counter sale banned by, 94
immunoassays approved by, 22
and warfarin, 164

Food supplements, herbal remedies as, 355

Forensic investigations, direct measurement of warfarin in, 173

Formulation, drug
enteric-coded, 388
immediate-release, 387–388
sustained-release, 388

Fosphenytoin, 269–270

Foxglove (Digitalis purpurea), 186, 187
digitalis glycosides derived from, 237
digoxin immunoassay for, 192, 192, 194
poisoning from, 189, 193–194
toxicity of, 187

French paradox, 125

Gabapentin, 285
Gamma-butyrolactone, chemical structure of, 88
γ-glutamyltransferase (GGT), in kava consumption, 195

Gamma-hydroxybutyric acid (GHB)
chemical structure of, 88
commercial availability of analogs of, 95
identification of, 85
mortality associated with, 94
overdose, 96
over-the-counter sale banned by FDA, 94
routine screening of, 96
testing for, 37
in toxicology screen, 414, 415, 416
Gamma-hydroxybutyric acid (GHB) withdrawal
case study, 38
mimicking schizophrenia, 94

Garlic (Allium sativum) supplements, interaction with drugs of, 373, 374–375

Gas chromatography (GC), 19
alcohol determination using, 416
for anticonvulsants, 266
in blood alcohol determination, 132–135, 134
of ethylene glycol, 154, 156
of various alcohols, 132–135, 134

Gas chromatography/mass spectrometry (GC/MS), vii, 53
for confirmation of positive results, 22
for determination of blood alcohol, 133–134
in plant poisoning or toxicity, 191
psilocin detection with, 105

Gastroesophageal reflux disease (GERD), and breath alcohol analyzer results, 130

Gatifloxacin, interference with opiate immunoassay of, 61

Gel, in serum separator tubes, 218–222, 219

Gelsemine, 188

Gender differences
in alcohol metabolism, 122–123, 124
in drug disposition, 9, 11–13
in pharmacokinetics, 12

Genetic polymorphism
of cyclosporine, 326, 329–330
and phenytoin metabolism, 283
of tacrolimus, 330
in tolerance to warfarin, 163, 164–165
Genetic variation, 386
and pharmacogenomics, 389
and response to drug therapy, 388
Gentamicin, and serum digoxin levels, 244
German Commission E monograph, 355, 358
Germander
fatality associated with, 187
liver toxicity associated with, 196, 196–197, 206
medical uses for, 196
Germany, herbal monographs in, 355–356, 358
Gewodin tablets, false-positive test results with, 69
Ginkgo biloba, interaction of various drugs with, 373, 373–374
Ginsengs
and antidiabetic medication, 378
and digibind therapy, 194–195
interaction of drugs with, 371
Siberian, 257
Glasgow coma scale, 142, 417
in carbamazepine toxicity, 307
level of consciousness measured by, 203
in pesticide poisoning, 147
in TCA overdose, 312
in traumatic brain injury, 283
Glass tubes, compared with plastic tubes, 216–217, See also Specimen collection
Gliclazide, interaction of St. John’s wort with, 369, 372
Glucose-6-phosphate dehydrogenase (G6PD), 392–393
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
drugs to avoid in patients with, 393, 393
measuring, 393–394
and medication, 392–394, 393, 395
in neonates, 394
prevalence of, 393
testing for
indications for, 393
molecular methods for, 393–394
Glucose-6-phosphate dehydrogenase (G6PD) gene, mutation in, 393
Glue abuse, 101, 114–115
case study, 115–116
long-term, 116
Glutaraldehyde, as urine adulterant, 45
P-glycoprotein in disposition of digoxin, 365
in St. John’s wort metabolism, 361
Glycosides toxic plant, 188–189
from uzara roots, 194
Glycyrrhizic acid, 198
Golden chain (Laburnum), 186
Goldenseal, interaction with drugs of, 377
Goldenseal tea, as adulterant, 42, 43
Grainer tube vacutee, 219, 219, 222
Grapefruit juice, and warfarin, 171
Green tea, interaction with warfarin of, 171
Guarana, 201
Hair analysis, 47, 48
Hallucinogens, 21, 101
Haloperidol, therapeutic range for, 315
Hamilton Depression (HAMD) Scale, 300
Hawthorn, interaction with drugs of, 377
Health care professionals, herbal supplement use of, 357
Health Inca tea, 78
Heart failure, statistics for, 237
Heavy metals, specially designed collection tube for, 216
Hemlock, poison, 204
Hemodialysis and digoxin therapy, 238
and DLIS, 247–248
for ethylene glycol poisoning, 156
in methanol poisoning, 151
Hemoglobin, interference with therapeutic drug monitoring of, 230
Hemolysis avoiding, 232
in spectrophotometric methods, 231
during therapeutic drug monitoring, 230
Hemp products, THC content in, 71
Heparin
  as anticoagulant for specimens, 214–215
  interference with EMIT of, 215
Hepatitis infection, and drug clearance, 14
Hepatotoxicity
  with herbal supplements, 195–194, 196
  in plant poisoning, 195–197, 196
Hepatotoxins, 195
  “Herbal ecstasy,” 199
  “Herbal highs,” 96
Herbal remedies
  adulterated, 418–419
  popularity of, 355
Herbal supplements, See also Drug-herb interactions
deaths associated with, 186–187, 187
  interactions of warfarin with, 169–170, 170
  interference with digoxin assays of, 246, 247, 255–257, 257
  liver toxicity caused by, 378
  most commonly used, 356, 358
  patient reporting of, 377–378
  plant poisoning and toxicity from, 190–191
  popularity of, 378
  sales of, 355, 356
  toxicity of, 206
Herbal toxicity
  abnormal laboratory tests in, 197–198
  aconite poisoning, 201
  diagnosis of, 198–199, 199
  digoxin immunoassay in detection of, 192, 192–195
  liver function tests as indication of, 195
  mortality associated with, 202
Herbathin, 59
Herb-drug interactions, see Drug-herb interactions
Heroin (diacetylmorphine)
  identification of, 91
  positive opiate test results with, 72
Heterophilic antibodies
  interference in therapeutic drug monitoring of, 422
  types, 422
Highly active antiretroviral therapy (HAART), 284, 285
  for AIDS patients, 20
  interactions of St. John’s wort with, 364
High performance liquid chromatography (HPLC), 19
  of acetaminophen concentration, 423
  for analysis of magic mushrooms, 106
  for analysis of non-TCAs, 316
  for analysis of TCAs, 313
  of anticonvulsants, 266
  for mescaline determination, 269, 270
  in plant poisoning or toxicity, 191
High performance liquid chromatography -mass spectrometry (HPLC-MS)
  analysis, of immunosuppressants, 345
High performance liquid chromatography -tandem mass spectrometry (HPLC/MS/MS), for analysis of TCAs, 313
High performance liquid chromatography with ultraviolet detection (HPLC-UV)
  of immunosuppressants, 336–337, 343–345, 345
  for mycophenolic acid, 343
Hook effect, of HAMA effect, 425, 425
Hormonal contraceptives, interaction with antiepileptic drugs of, 12
Hormonal replacement therapy, interactions with St. John’s wort of, 369
Hue Dian Shen Ying Jiao Nang Yi Hao, 419
Human anti-animal antibodies (HAAAs)
  and digoxin measurement, 249–250
  properties of, 422
Human anti-mouse antibody (HAMA)
  hook effect of, 425, 425
  occurrence of, 422
Human chorionic gonadotropin (hCG) test, false-positive test result, 412
Human genome, 386
Human Genome Project, 385
Hunter Serotonin toxicity criteria, 314
Hydrocodone
  positive test results for, 74
  in protocol for opiate testing, 73
Hydrogen peroxide, as adulterant, 42, 43
Hydromorphone
  positive test results for, 74
  in protocol for opiate testing, 73
Hydroxyamphetamine, 68
5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH), 267–268
Hydroxyzine
  chemical structure of, 303
  interference with TCA immunoassays of, 302, 310–311
Hyperbilirubinemia
  atazanavir-associated, 400
  severe neonatal, 394
Hyperforin, 360
  chemical structure of, 361, 362
  in CYP3A induction by St. John’s wort, 361
Hypericum, in St. John’s wort, 360, 361
Hypoalbuminemia
  in elderly, 281
  free anticonvulsant concentrations in, 279
  in patients with hepatic dysfunction, 14–15
Hypoglycemic agents, interaction with St. John’s wort of, 369
Hypothalamus-pituitary adrenal axis, and response to antidepressants, 401
Icterus, in spectrophotometric methods, 231, See also Jaundice
Ill, critically, free anticonvulsant concentrations in, 279, See also Chronically ill
Imatinib, interaction of St. John’s wort with, 365–366
Imipramine
  chemical structure of, 294
  effectiveness of, 296
  therapeutic range for, 293, 294
Imunoassays, see also specific immunoassays
  antibodies used in, 18–19
  cut-off concentrations of, 22
  effect of heterophilic antibodies on, 422–423
  heterogeneous, 18
  homogeneous, 17–18
  immunoassays for, 337
  for initial screening, 53
  interferences in, 53
  limitations of, 20
  for screening for abused drug in urine, 25
  for therapeutic drug monitoring, 17–19
Immunoglobulins
  human anti-animal antibodies in, 422
  negative interference caused by, 424
Immunological adverse reactions, 402
Immunosuppressants
  immunoassays for
    commercially available, 335
    limitations of, 337–343
    interactions of St. John’s wort with, 362–364, 372
    mechanism of action of, 324
    monitoring of, 1
    and pharmacogenomics, 398–399
    pharmacogenomics testing of, 398–399
    and St. John’s wort, 360
    therapeutic monitoring of, 8–9, 10, 347
    chromatographic methods, 343, 345–347
cyclosporine, 326, 329–330, 337–341
everolimus, 332–333, 341–343
mycophenolic acid, 333–335, 334, 341–343
sirolimus, 331, 341–343
tacrolimus, 330–331, 337–341
uses for, 323
Infants, See also Neonates
  and drug-herb interactions, 359
  exposed to paroxetine, 402
Information, drug information compendiums, 168
Infrared (IR) spectroscopy, for breath alcohol analyzers, 129
Inhalant abuse
adverse effects of, 116
complications of, 117
fatality associated with, 117
Inhalants, commonly abused, 114, 115
Inosine monophosphate dehydrogenase (IMPDH), 333
Insecticide poisoning, See also Pesticide poisoning
case reports, 145
nonoccupational exposure to, 141
Intect 7, 46
Interferences, See also Discordant specimen/interference eliminating, 426
resolving analytical, 424–426, 425
Intermediate metabolizers (IMs), 390, 394
Intermediate syndrome, 143–144
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, 6
International normalized ratio (INR), 162–163, 164
and herbal supplements, 364
unexpected, 419
unexpected changes in, 179
Intoxilyzer 5000, 130
Ipriflavone, interaction with drugs of, 377
Irinotecan
interaction with St. John’s wort of, 366
pharmacogenomics of, 396
Jaundice
bilirubin in, 227
in spectrophotometric methods, 231
Jequirity peas (Arbus precatorius), 186
Jimsonweed (Dutra stramonium)
hepatotoxicity of, 196, 197
toxicity of, 187
JWH-018
analysis of, 97
chemical structure of, 88
as spice, 96
Kava
fatality associated with, 187
hepatotoxicity associated with, 195–196, 196, 206, 378
interaction with drugs of, 373, 375–376
Kelt supplementation, effect on thyroid function of, 198
Ketamine, 415, 416
chemical structure of, 88
identification of, 85
testing for, 37
Ketogenic diet, 131–132
Khat (Catha edulis Forsk), 110
abuse of, 110, 112–113
active components of, 103
amphetamine compared with, 112
detection of, 113–114
street names for, 103
Khat chewing, 112
Kinetic Interaction of Microparticle in Solution (KIMS) Immunoassay, 45
Korean herbal tonic, 198
Labetalol, interference with amphetamine immunoassays of, 60
Laboratory testing, STAT, errors in, 225, 225
Lactate dehydrogenase (LDH), in misinterpretation of alcohol analysis, 133
Lactic acid measurement, ethylene glycol interference with, 156
Lamotrigine, 285
carbamazepine toxicity caused by, 271
during pregnancy, 13
“Legal highs,” 96
Levetiracetam, 285
Liberation, drug, 387
Licorice
hypokalemic myopathy induced by, 198
interaction with drugs of, 373, 377
Lipemia, in spectrophotometric methods, 231
Lipid content, and therapeutic drug monitoring, 230–232
Lipoproteins, 230
Liquid chromatography/mass spectrometry (LC-MS), of immunosuppressants, 336–337, 345–347
Liquid chromatography/tandem mass spectrometry (LC-MS/MS)
for analysis of TCAs, 313
for antiretroviral drugs, 20
for determining patient compliance, 35
for digoxin analysis, 245
for everolimus, 342
of immunosuppressants, 336–337, 338, 345, 346–347
for mycophenolic acid, 342
for sirolimus, 341–342
for tacrolimus, 340
for therapeutic monitoring of digoxin, 258
Lisdexamfetamine (Vyvanse)
chemical structure of, 70
positive amphetamine test results for, 70
Lithium therapy
fatality associated with, 215
therapeutic monitoring of, 214–215
Liver cirrhosis, 128
Liver disease
and drug disposition, 14–15
free anticonvulsant concentrations in, 278
Liver function tests, in plant poisoning or toxicity, 191
Liver toxicity, and herbal supplements, 378, See also Hepatotoxicity
Lobelia (Lobelia inflata), diagnosis of poisoning with, 205
Loperamide, interaction with St. John’s wort of, 370–371
LSD, testing for, 39
Lu-Shen-Wan
digoxin immunoassay for identifying, 192, 192
eliminating interferences caused by, 258
interference with digoxin assays of, 256
Magic mushroom abuse, 102–103, See also Mushrooms
Ma Huang, chromatographic analysis of, 199, 199–201
Mammalian target of rapamycin (mTOR) inhibitors, 324
Maprotiline
therapeutic monitoring of, 314
therapeutic range for, 315
Marijuana analogs, as designer drugs, 96–97
Marijuana metabolite (11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid [THC-COOH])
positive confirmation of, 36
storage of specimens for, 217–218
testing for, 23
Marijuana products, in U.S., 71–72
Marijuana test results, true-positive, 70–72
Marinol, uses for, 70–71
MASK Ultrascreen, 46
Mass spectrometry (MS), See also Gas chromatography/mass spectrometry
for analysis of TCAs, 313
of anticonvulsants, 266
in combination with GC, 19–20
Mebeverine, false-positive results with, 68
Meconium, testing of, 47
Medical drug testing, 31, See also Workplace drug testing
challenges for, 32
limitations of, 35
Medical review officer, in workplace drug testing, 31
Medication, discontinued, and discordant specimen, 421, See also Prescription medication
Meperidine analogs, as designer drugs, 93
Mephedrone (4-methylmethcathinone), 113
6-mercaptopurine, pharmacogenomics of, 396
Mescaline, *See also* Peyote cactus
abuse of, 108–109
analysis of, 109
chemical structure of, 107, 108
mass spectrum of, 110, 111
mortality associated with, 109–110
Metabolic acidosis, of methanol toxicity, 150
Metabolism, and pharmacological action
of drug, 387–390, 389
Metabolism, drug, 387, 388
enzymes in, 388, 389
first-pass, 388
polymorphism in cytochrome P450, 390–391
polymorphism of thiopurine methyl transferase in, 392
polymorphism of transporter proteins
and receptors, 391–392
Metabolizers, classification of, 389–390
Methadone
interaction of St. John’s wort with, 370, 372
interference with immunoassays of, 62, 62
in routine opiate screening, 73
testing for, 24
Methamphetamine
chiral analysis of, 58–59
mass spectral fragmentation pattern
for, 56, 57
testing for, 22–23
*L*-methamphetamine, in Vicks inhaler, 58
Methamphetamine test results
drugs causing positive, 69, 69
positive, 67–70, 69
Methanol
blood levels for, 149
human exposure to, 147–148
lethal dose of, 149
metabolism of, 148–150
uses for, 147
Methanol poisoning, 132, 139
blindness associated with, 149
case report, 148
deaths attributed to, 150
fatality associated with, 148
hemodialysis in, 151
laboratory diagnosis of, 150–152
Methcathinone, 112
abuse of, 112
detection of, 113
synthesis of, 113
Methotrexate, therapeutic monitoring of,
8, 396–397
Methyldigoxin, 252
3,4-methylenedioxymethamphetamine
(MDA), 54, 86
chemical structure of, 87
cross-reactivities with amphetamine
immunoassays of, 54, 55
3,4-methylenedioxyamphetamine
(3,4-MDMA) (Ectasy), 54, 86, 89
chemical structure of, 87
cross-reactivities with amphetamine
immunoassays of, 54, 55
detection of, 37
testing for, 33
3,4-methylenedioxy-N-ethylamphetamine (MDEA), 33, 89
Methylephedrine, identification of, 113
α-methylfentanyl, chemical structure of,
87
N-methyl-N-trimethylsilyl trifluoroacetamide
(MSTFA), in analysis of psilocin
by GC/MS, 106, 107
Methyl parathion, poisoning with, 143
Methyphenidate, positive amphetamine
drug screen with, 68
Metronidazole, interaction with warfarin
of, 166
Miconazole, interaction with warfarin of, 167
Microparticle enzyme immunoassay
(MEIA)
of digoxin, 248, 253, 254
false-positive tacrolimus results in,
230
major interferences in, 344
for sirolimus, 341
for tacrolimus, 339
Midazolam, interactions of St. John’s
wort with, 366
Mirtazapine, therapeutic monitoring of,
314
Mistletoe
  in folk medicine, 196, 197
  hepatitis associated with, 196, 197
  hepatotoxicity of, 206
Mitochondrial acetoacetyl-CoA thiolase
deficiency, 5
Modular P800 analyzer, 274
Molecular alterations, in
pharmacogenomics, 389
Molecular genetic testing, of enzymatic
activity, 389–390
Monkshood (Aconitum napellus), 186, 187
  fatality associated with, 187
  mortality associated with, 202
  toxicity of, 187
Monoamine oxidase inhibitors, 295, 314
Morphine
  chemical structure of, 76
  positive confirmation of, 36
  positive test results for, 74
Morphine-to-codeine ratio, 72
Morphine-3-glucuronide, testing for, 24
Motor vehicle accidents, alcohol-related, 126
MTOR inhibitors, mechanism of action
of, 325
Multiple myeloma, 423
Multiple reaction monitoring (MRM), 175
Mushroom poisoning, 185
Mushroom(s)
  diagnosis of poisoning from, 105–106,
  106
  psychoactive, 102
Mushrooms, magic, 101
  active ingredients in, 101–102, 102, 103
  fatality from, 105
  street names of, 103
  toxicity of, 103–105, 117
Mycophenolate mofetil (CellCept), 333
  adverse effects from, 334–335
  metabolism of, 333
Mycophenolate sodium, chemical
structure of, 334
Mycophenolic acid (MPA), 333
  chemical structure of, 334
  immunoassays for
  commercially available, 335
  limitations of, 342
  major interferences in, 344
  interaction of St. John’s wort with, 364
  metabolism of, 334
  therapeutic monitoring of, 326
  therapeutic range of, 334
Mycophenolic acid mofetil
  chemical structure of, 334
  enteric-coded formulation of, 388
Naproxen, and false-positive results, 62
Narcotic analgesics, 21, See also Opioids
National Academy of Clinical
  Biochemistry’s Laboratory
  Medicine Practice Guidelines, 55
National Committee for Clinical
  Laboratory Standardization,
  EP7-P protocol of, 227
National Institute of Alcohol Abuse and
  Alcoholism, 124
National Institute on Drug Abuse
  (NIDA), 23, 32
Neonates
  altered pharmacokinetics in, 15–16
  exposed to paroxetine, 402
  G6PD deficiency in, 394
Neoral, 326
Nicotinamide adenine dinucleotide
  (NAD), in enzymatic automated
  analysis of alcohol, 133
Nifedipine; interaction of St. John’s wort
  with, 365, 372, See also
  Cardioactive drugs
Nightshade, See also Pokeweed
  deadly, 186
  poisoning with, 191, 204
Nitrite, adulteration with, 44
Nitrogen phosphorus detector (NPD),
  for analysis of TCAs, 313
Nonnucleoside reverse transcriptase
  inhibitors (NNRTIs)
  and St. John’s wort, 360
  therapeutic monitoring of, 400
Nonsteroidal anti-inflammatory drugs
  (NSAIDs)
  false-positive results produced by, 61
  interaction with phenytoin of, 282
  interaction with warfarin of, 165, 167
Nortriptyline
chemical structure of, 294
pharmacogenomics of, 401
therapeutic monitoring of, 300–301
therapeutic range for, 293, 294
Nursing mothers, and drug-herb interactions, 359
Nutmeg
diagnosis of poisoning with seeds of, 204
toxicity of, 205
Older adults, herbal supplement use of, 357, See also Elderly
Oleander (Nerium oleander), 186
poisoning from, 189
toxicity of, 187, 256–257
varieties of, 256
Oleander plant poisoning
case study, 193
digoxin immunoassay for identifying, 192, 192
fatalities from, 193
treating, 206
Oleander tea, fatality associated with, 187
Oleandrin
chemical structure of, 254, 255
eliminating interferences caused by, 258
interference with digoxin assays of, 256
Omeprazole
interaction of St. John’s wort with, 372
interaction of wort with, 370
interaction with warfarin of, 167
pharmacogenomic testing of, 395
Opiate abuse, 53
Opiate immunoassay, interferences with, 60–61
Opiates, 21
interference with immunoassays of, 62, 62
pharmacogenomic testing of, 395
testing for, 23–24
Opiate test results, true-positive, 72–75, 74
Opioid designer drugs, 91–93
fentanyl, 92
fentanyl analogs, 92–93
heroin, 91
meperidine analogs, 93
Opioids
cross-reactivity in testing for, 38, 38–39
interaction of St. John’s wort with, 372
patient compliance with, 36
positive test results with, 73, 74
Opioid therapy
case studies, 398
fatality associated with, 397
pharmacogenomics and, 397–398
OPUS digoxin assay, 253
Oral contraceptives
interaction of St. John’s wort with, 369–370, 372
interaction with antiepileptic drugs of, 12
Oral fluid, testing, 47–48
Organochlorines, 140
Organophosphate poisoning, 139
case report, 142
cholinesterase in diagnosis of, 145–147
clinical symptoms of, 143, 144
and intermediate syndrome, 143–144
occurrence, 141–143
oxime treatment in, 147
treatment for, 144
Organ transplantation, role of
cyclosporine in, 323–324
Organ transplant recipients
and drug-herb interactions, 359
and pharmacogenomics testing, 398–399
Osmolar gap
calculating, 151
in methanol and ethylene glycol poisoning, 157
Overdose
acetaminophen (paracetamol), 2
death related to, 2
digoxin, 252
GHB, 96
with negative toxicology report, 414–416
with SSRI, 301
with TCAs, 297–298, 301
testing for, 25
warfarin, 172
Over-the-counter medications and amphetamines, 23
interference with immunoassays of, 62–63
Oxcarbamazepine, chemical structure of, 268
Oxalates, as plant toxins, 189–190
Oxcarbazepine, in treatment of epilepsy, 274
Oxcarbazepine-phenytoin 2C19 interaction, phenytoin toxicity and, 284
Oxycodone
  case study of fatality associated with, 74
cross-reactivity of opiate assays with, 38, 38
  positive test results for, 74
  in protocol for opiate testing, 73
testing for case study, 39
  false-positive results, 39
  results, 72
Oxymorphone, 72
  positive test results for, 74
  in protocol for opiate testing, 73
Pain management, see Opioid therapy
Papain cleavage, to produce Fab fragment, 251–252
Para-methoxyamphetamine (PMA), 89, 90
Para-methoxy-methamphetamine (PMMA), 89, 90
Paremyd eye drops, 68
Paroxetine
  case study for, 402
  chemical structure of, 295, 295
  newborn exposure to, 315
  pharmacogenomics of, 402
  therapeutic range for, 315
Particle-enhanced turbidimetric inhibition immunoassay (PETINIA), 255
for carbamazepine, 272–273, 274
  false-positive carbamazepine levels with, 274
  phenytoin, 424
Patient compliance with opioid drugs, 36
  and therapeutic drug monitoring, 8
  urine drug testing for, 35
Patient identification, incorrect, 225
Peak and trough drug levels, for therapeutic drug monitoring, 8
Penicillins, interaction with phenytoin of, 283
Pennroyal oil, fatality associated with, 187
Peptides, potential toxicity of, 190
Pesticide poisoning, 139, See also insecticide poisoning of agricultural workers, 140–141
case reports, 143
in China, 141
diagnosis of, 140
occurrence, 140–141
Pesticides
  active ingredients of, 11, 140
classification of, 140
Peyote cactus (lophophora williamsii), 101
  active components of, 101–102, 103
description, 107
diagnosis of poisoning with, 109–110
legal ingestion of, 108
mescaline content of, 108
mortality associated with, 109–110
street names for, 103
toxicity of, 108–109, 117
P-glycoprotein
  in disposition of digoxin, 365
  in St. John’s wort metabolism, 361
Pharmacogenetics, defined, 386
Pharmacogenomics
  classification of patients in, 394
  defined, 386
  and genetic variability, 389
  methodologies, 403–404, 404
in pharmacotherapy, 394
  anticancer drugs, 396–397
  antiretroviral drugs, 400
  cardioactive drugs, 399–400
  immunosuppressants, 398–399
  opioid therapy, 397–398
  psychoactive drugs, 401–402
  and warfarin therapy, 396
polymorphism in cytochrome P450, 390–391
Pharmacogenomics (cont’d)
  polymorphism of thiopurine methyl transferase in, 392
  polymorphism of transporter proteins
  and receptors, 391–392
  of TCAs, 298–299
  in therapeutic drug-monitoring
  practice, 405
Pharmacogenomics biomarkers, in
  FDA-approved drug labels, 405,
  405
Pharmacogenomics testing
  clinical significance of, 395
  costs of, 403
  goal of, 385, 386
  as proactive approach, 394
  successful, 387
Pharmacogenomics tests
  FDA-approved, 404, 404
  in toxicology laboratory, 403
Pharmacokinetics
  and age, 15–16
  gender differences in, 12
  and genetic variations, 386
Pharmacotherapy
  and genetic variations, 388
  ineffective, 386
  role of pharmacogenomics in, 394–401
Phencyclidine (PCP)
  immunoassays of
    false-positive results, vii, 61
    interference with, 62, 62
    testing for, 24–25
Phencyclidine analogs, as designer drugs,
  93–94
Phenethylamine, designer drugs related
to, 91
Phenobarbital, 265, 277
  chemical structure of, 268
  therapeutic range for, 276
Phenobarbital immunoassays,
  interferences in, 275
Phenothiazine, interferences with TCA
  immunoassays of, 302, 305–306
Phenotyping, biochemical tests for,
  394
Phenprocoumon
  analysis of, 175
  electrospray mass spectra of, 176
Phenytoin
  absorbed by barrier gel, 221
  in AIDS patients, 282
  chemical structure of, 268
  free level of, 420–421
  monitoring free concentrations of, 277
  monitoring free drug concentrations
    for, 286
  protein binding of, 277, 278
  therapeutic monitoring of, 265
  therapeutic range for, 276
Phenytoin immunoassays, interferences
  in, 266–270, 267, 268
Phenytoin-oxacillin interaction, 283
Phenytoin toxicity, 282
  case studies, 283–284
  in thyroid dysfunction, 283
Phlebotomy collections, See also
  Specimen collection
    timing of, 224
    tubes for, 216–217
Physicians, and laboratory errors, 413
Physostigmine, 188, 191
Piperazine, designer drugs derived from,
  89
Plantain (plantago major)
  medical uses of, 194
  toxicity of, 194
Plant poisoning(s)
  abnormal laboratory tests in, 197–198
  accidental, 185
  case studies, 191, 193, 196, 198, 200,
    205
  diagnosis of, 198–199, 199
    angel’s trumpet, 203
    castor bean (ricin), 202–203
    weight loss products, 199, 199–201
  digoxin immunoassay in detecting,
    192, 192–195
  hepatotoxicity associated with, 195
  with herbal medicines, 186–187, 187
  liver function tests as indication of,
    195
  and role of clinical laboratory, 190–191
  toxicity of, 185–187, 206
  toxins responsible for, 187–188
    alkaloids, 188
    amino acids, 190
    coumarin compounds, 189
essential oils, 190
glycosides, 188–189
oxalates, 189–190
peptides, 190
proteins, 190
saponins, 189
Plants, poisonous, 185
identification of, 186
toxicity of, 186, 187
Plasma specimens, protein interference with, 423
Plastic tubes, compared with glass tubes, 216–217
P450 mixed function oxidase, 388
Pokeweed (American nightshade) diagnosis of poisoning with, 204
toxicity of, 187
Poor metabolizers (PMs), 390, 394
Poppy seeds, positive opiate results with, 75
Potassium canrenoate eliminating interferences caused by, 258
interference with digoxin immunoassays of, 247, 253–254
Preanalytical errors, 232, See also Therapeutic drug monitoring results
Pregabalin, 285
Pregnancy
drug disposition during, 12–13
drug-herb interactions in, 359
false-positive interpretation during, 418
molar, 425
monitoring anticonvulsants during, 281
Pregnan X receptorP-glycoprotein, in St. John’s wort metabolism, 361
Prenylamine, false-positive test results with, 69
Prescription medications, See also specific medications
abuse of, 21
with amphetamine or methamphetamine, 68
Probe drug, 394
Propoxyphene positive test results for, 74
in routine opiate screening, 73
Propylene glycol, in analysis of ethylene glycol, 155
Protease inhibitors interaction of St. John’s wort with, 372
interactions of St. John’s wort with, 364
and St. John’s wort, 360
therapeutic monitoring of, 8–9, 400
Protein binding, of drug, 387, 388
Proteins, potential toxicity of, 190
Proton pump inhibitors, interaction of St. John’s wort with, 372
Protriptyline, therapeutic range for, 293, 294
Pseudocholinesterase, 145–146
Pseudoephedrine false-positive test results with, 56–57
misidentification of, 56
Psilocin, 102
chemical structure of, 102
psychoactive effects of, 103
Psilocin glucuronide, identification of, 106
Psilocybe cubensis, 103, 104
Psilocybin, 102
chemical structure of, 102
ingestion of, 103
toxicity from, 105
Psychoactive drugs, pharmacogenomics of, 401–402
Psychoactive substances, hospital admission statistics for, 1
Psychotropic drugs, interaction with warfarin of, 166
Pyrrolizidine alkaloids, 188
Quantifier mass transitions, 346
Quantitative microparticle system (QMS) for everolimus, 342
major interferences in, 344
Quazepam, interactions of St. John’s wort with, 366, See also Benzodiazepines
Quetiapine, 271
chemical structure of, 304
interference with TCA immunoassays of, 302, 309–310
Quinidine
  and digoxin toxicity, 238
  interaction with digoxin of, 243
Quinidine therapy, and renal clearance 
of digoxin, 8
Quinolones, interference with opiate 
immunoassays of, 60, 61
Radioimmunoassays (RIAs), and DLIS, 
248
Ranitidine, interference with 
amphetamine immunoassays of, 
60
Rapamycin, 331, See also Sirolimus
Rave party drugs, identification of, 85, 
See also Club drugs
Reagent carryover, suspected, 417
Reanalysis of specimens, 426
Renal disease 
  and drug disposition, 13 
  and risk of digoxin toxicity, 242, 
  242
Renal function tests, in plant poisoning 
or toxicity, 191
Respiratory agents, interaction of St. 
John’s wort with, 372
Ricin, 186 
  properties of, 202 
  toxicity of, 187, 190
Ricin poisoning 
  symptoms of, 202 
  treatment for, 202–203
Rifampicin, interference with opiate 
immunoassays of, 60
Rifampin, interaction with warfarin of, 
167
Roche assay, interferences of Chinese 
medicine in, 256
Rodenticides 
  determination of, 179 
  indandione, 179
Rohypnol (flunitrazepam) 
  chemical structure of, 87 
  detection of, 414
Rosuvastatin, interaction of St.John’s 
wort with, 368
Royal Dutch Association for 
Advancement of Pharmacy, 
405
Safety issue, of discordant specimens, 
426, See also Discordant 
specimen/interference
St. John’s wort 
  active components of, 360 
  adverse effects of, 359–360 
  case studies involving, 362–363, 
  367–368, 369–370 
  chemicals isolated from, 359 
  drug interactions with, 358–360, 359, 
  378 
  agents acting on respiratory system, 
  367–368 
  with antibiotics/antifungals, 370 
  anticancer drugs, 365–366 
  antidepressants, 366–367 
  antiepileptic agents, 368 
  anti-HIV agents, 364 
  antihyperlipidemic agents, 368 
  benzodiazepines, 366–367 
  cardioactive drugs, 365 
  hypoglycemic agents, 369 
  immunosuppressants, 362–364 
  mechanism of interaction in, 360 
  oral contraceptives/hormonal agents, 
  369–370 
  warfarin, 364 
  subtherapeutic drug level due to, 420
Salicylate, chemical structure of, 2, 3
Salicylate assays, 2 
  bilirubin interference with 
  colorimetric, 229 
  chromatographic methods, 4–5 
  commercially available, 4 
  interferences with, 5
Salicylate poisoning 
  case studies, 3–4 
  statistics for, 2
Salicylate toxicity, delayed, 2, 3
Salsalate, chemical structure of, 2, 3
SAMHSA (Substance Abuse and 
Mental Health Services 
Administration), 21, 32 
  adulterant detection guidelines of, 46 
  drug-testing programs of, 33 
  federally mandated drugs of, 76
SAMHSA (Substance Abuse and 
Mental Health Services 
Administration) drugs
INDEX

453

cut-off concentrations of, 33, 33
detection window for, 34, 34
mandated testing of, 35
Sandimmune, 326
Saponins, 189
Selective serotonin reuptake inhibitors (SSRIs), 295, 316–317
for chronic pain, 296
interaction of St. John’s wort with, 366, 372
interaction with warfarin of, 165
overdoses with, 301
therapeutic monitoring of, 314
Selegiline, test results with, 69, 69, 70
Serial dilution, to confirm interfering substance, 424–425, 425
Serotonin-norepinephrine reuptake inhibitors (SNRIs), 295
Serotonin syndrome, 314, 402
Sertraline
chemical structure of, 295, 295
therapeutic range for, 315
Serum separator tubes (SSTs), 218
gel for, 218–222, 219
problems with, 411
stability of drugs in, 219–222
types of, 219, 219
Seville orange, 200
Siberian ginseng, in serum digoxin measurement, 257
Simvastatin, interaction of St. John’s wort with, 368, 372
Single nucleotide polymorphism (SNP), in pharmacogenomics, 385
Sirolimus
adverse effects of, 331–332
chemical structure of, 328
drug interactions with, 324
immunoassays for
commercially available, 335
limitations of, 341–342
major interferences in, 344
mechanism of action of, 325
metabolism of, 332
therapeutic monitoring of, 331–332
therapeutic range for, 332
S-Monovette serum tubes, 222
Soap, as adulterant, 41, 42, 43
Solvent abuse, 101, 114, 117
adverse effects of, 116
nonspecific symptoms of, 116
serious consequences of, 117
Solvent blank, running, 416
Soy milk, interaction with warfarin of, 169
Specimen collection, See also Urine specimens
from central lines, 226
coagulant for, 214
for heavy metals determination, 216
problems with, 411
for reanalysis, 426
standardized, 413
Specimen integrity tests, 43
“Spice,” 96, 97
Spirobolactone
chemical structure of, 254, 255
and digoxin toxicity, 238
eliminating interferences caused by, 258
interference with digoxin immunoassays of, 253–256
Statins, interaction of St. John’s wort with, 368
STAT laboratory testing, errors in, 225, 225
Stealth, adulteration of specimens with, 44–45
Steroidal alkaloids, 188
Steroid glycosides, 189
Stevens-Johnson syndrome, 402–403
Stimulants, 21
Strychnine, 188
Sulfamethoxazole/trimethoprim, interaction with warfarin of, 166
Superwarfarin compounds
chromatography of, 178–179
development of, 173
Superwarfarin poisoning, 173–174, 179–180
Sympathomimetic amines, interference in amphetamine immunoassays of, 55–57, 57
SYNCHRON LX, Beckman digoxin assay on, 257
Syneprine, 200, 201
SZD RAD, 332, See also Everolimus
Table salts, as adulterants, 41, 43
Tacrolimus
chemical structure of, 327
dosing for, 324
drug interactions with, 324
immunoassays for
  commercially available, 335
  limitations of, 339–341
major interferences in, 344
interaction of St. John’s wort with, 363, 364
mechanism of action of, 324–325
pharmacokinetics of, 330
therapeutic monitoring of, 330–331
therapeutic range of, 331
toxicity of, 399
Talinolol, interaction with St. John’s wort of, 365
Tamoxifen, pharmacogenomics of, 396
Tandem mass spectrometry (MS-MS),
  See also Liquid chromatography/
tandem mass spectrometry
for mescaline determination, 110
for testing drugs of abuse, 25–26
TDM, see therapeutic drug monitoring
Tetracycline, interaction with digoxin of, 243
Tetrahydrocannabinol (THC)
  (dronabinol)
interference with immunoassays of, 62, 62
  synthetic, 70
Tetrahydrocannabinol (THC)
  (dronabinol) analysis, collection tubes for, 217
Delta-9-tetrahydrocannabivarin
  (THCV), urine tests with, 71
11-nor-delta-9-tetrahydrocannabinol
  -9-carboxylic acid (THC-COOH),
  storage of specimens for, 217–218
Delta-9-tetrahydrocannabinol (THC;
marijuana), 70–71
THC, see tetrahydrocannabinol
Thebaine
chemical structure of, 76
as marker for poppy seed consumption, 75
Theophylline, interaction of St. John’s wort with, 367–368, 372
Therapeutic drug monitoring (TDM),
  See also Toxicology laboratories
analytical methods for, 17, 213
  chromatographic methods, 19–20
  immunoassays, 17–19
of anticonvulsants, 265
carbamazepine, 267, 270–275, 271, 272
case studies, 283–285
interferences in, 266, 267
phenobarbital, 275
phenytoin, 266–270, 267, 268
valproic acid, 275
appropriate collection tubes for, 216,
  216–218
in cardiovascular disease, 15
in children, 15–16
of commonly used drugs, 10
defined, 6
defered, 238, 239–245, 240, 242
  drugs requiring, 7, 8–9, 10, 11
effect of gender on, 9, 11–13, 12
effect of high lipid content on,
  230–232
in elderly, 15–16
erroneous results in, viii, 213, 411
goal of, 385, 386
hypothesis for, 387
immunoassays for, 26 (see also
  Immunoassays)
of immunosuppressants, 347
  chromatographic methods, 343,
  345–347
cyclosporine, 326, 329–330
everolimus, 332–333
immunoassays vs. chromatography,
  335, 335–337, 344
mycophenolic acid, 333–335, 334
need for, 324
sirolimus, 331–332
tacrolimus, 330–331
interference of plants and herbal
  products in, 192, 192
of less common drugs, 11
limitations of, 26
in liver disease, 14–15
in neonates, 15–16
of newer antidepressants, 314–316, 315
in renal disease, 13
serum separator gel tubes for, 218–222, 219
in thyroid dysfunction, 16
traditional, 394, 404–405
of tricyclic antidepressants, 299–301
of warfarin, 162–165
Therapeutic drug monitoring results
effect of bilirubin on, 227–230
effect of hemoglobin on, 230
and gel separator tubes, 219, 219
preanalytical errors, 232
with central line draws, 226
STAT testing, 225
preanalytical factors
common errors, 224–225
documenting dosing time, 222–224
glass vs. plastic tubes, 216, 216–218
serum vs. plasma, 214–218, 216
statistics for, 224
suitability of SSTs, 218–222, 219
timing of collections, 224
Thiopurine methyl transferase,
polymorphism of, 392
Thioridazine, chemical structure of, 304
Thunder god vine (Tripterygium wilfordii)
diagnosis of poisoning with, 204
fatality associated with, 187
Thyroid dysfunction
and drug disposition, 16
and phenytoin metabolism, 283
Thyroid function, effect of kelp
supplementation on, 198
Tiagabine, 285
Tibolone, 370
Ticlopidine, interaction with warfarin of, 167
Tina-Quant digoxin assay, 255
Tobramycin, determination of, 215
Tolmetin, interference with EMIT
immunoassays of, 62
Toluene abuse, diagnosis of, 116, 117
Toluene-containing products, chronic
abuse of, 114–115
Topiramate, 285
Toxalbumin, 190
Toxic Exposure Survey, 2005, 2
Toxicity, See also specific drug toxicities
early indication of, 379
without symptoms, 421
Toxicology laboratories
acetaminophen assays in, 2–6, 3
blood alcohol testing in, 6
pesticide poisoning determination in, 157
salicylate assays in, 2–6, 3
tests performed in, 1
therapeutic drug monitoring in, 6–8
in cardiovascular disease, 15
drugs requiring, 8–9, 10, 11
effect of gender on, 9, 11–13, 12
in liver disease, 14–15
in renal disease, 13
in thyroid dysfunction, 16
Toxicology testing, unexpected drugs
found in, 415
Training, simulator-based
interdisciplinary, 413–414
Tranquilizers, 21
Transplant recipients
and drug-herb interactions,
359
and pharmacogenomics testing,
398–399
Transporter proteins
impact of genetic variations on, 389
polymorphism of, 391–392
Trazodone
interference with amphetamine
immunoassays of, 60
therapeutic monitoring of, 314
therapeutic range for, 315
Tricyclic antidepressants (TCAs)
absorption of, 296–297
cardiac toxicity of, 297
chemical structure of, 293, 294
chromatographic methods for
monitoring, 315–316
for chronic pain, 296
decreased use of, 293, 295
false-positive results for, 418
interaction of St. John’s wort with, 366,
372
mechanism of action of, 296
overdose, 297–298
pharmacogenomics of, 298–299
popularity of, 301
therapeutic drug monitoring of,
299–301
therapeutic effectiveness of, 297
Tricyclic antidepressants (TCAs) (cont’d)  
therapeutic monitoring of, 401  
with chromatographic methods, 312–314  
newer antidepressants, 314–316  
thefapeutic range for, 293, 294  
toxicology of, 298  
Tricyclic antidepressants (TCAs)  
imunoassays, 20, 301  
Abbott ADX total serum, 305  
interferences in, 301–302, 302, 303–304  
interferences with  
of antihistamines, 302, 310–312  
of carbamazepine, 302, 306–308  
cyclobenzaprine, 302, 312  
cyproheptadine, 302, 308–309  
phenothiazine and metabolites, 302, 305–306  
of quetiapine, 302, 309–310  
limitations of, 302, 305  
urine screening for, 305  
Trimipramine, therapeutic range for, 293, 294  
Trough blood level, for therapeutic drug monitoring, 8  
“Tryptamine” class of drugs, 102  
Turbidimetric immunoassay, phenytoin determination with, 267  
Ultrarapid metabolizers (UMs), 390, 394  
Ultraviolet detection, 19  
Uremic disease, free anticonvulsant concentrations in, 278  
Urine drug tests, limitations of, 48  
Urine Luck, as adulterant of specimens, 43–44  
Urine specimen(s), 47  
adulteration of, 48  
detection window of, 34  
for drugs of abuse testing, 21–22  
false-positive test results in, 412  
indications of diluted, 36  
for initial screening, 53  
screening of TCAs in, 308  
storage of, 218  
Urine toxicology screen, alternative reasons for positive, 80  
Uzara root (diuretic)  
in digoxin immunoassay, 192, 194  
glycosides from, 194  
Vaccination, during warfarin therapy, 169  
Valerian, interaction with drugs of, 373, 375–376  
Valproic acid  
in AIDS patients, 282  
in carbamazepine toxicity, 271–272  
chemical structure of, 268  
displacement of phenytoin by, 282  
free fraction for, 278  
free level of, 420–421  
in hypoalbuminemia, 279  
monitoring free drug concentrations for, 286  
therapeutic monitoring of, 265  
therapeutic range for, 276, 277  
Valproic acid immunoassays, interferences in, 275  
Valproic acid toxicity, 279–280, 284  
Vancomycin, therapeutic monitoring of, 8–9, 223  
Vegetables  
interaction with warfarin of, 171, 172  
rich in vitamin K, 171, 172  
Venlafaxine  
therapeutic monitoring of, 314  
therapeutic range for, 315  
Verapamil  
and digoxin toxicity, 238  
interaction of St. John’s wort with, 365, 372  
interaction with digoxin of, 243  
Very low density lipoproteins (VLDLs), 231  
Vicks inhaler, interference with  
anphetamine immunoassays of, 57–59  
Vigabatrin, 285  
Vinegar, as adulterant, 42, 43  
Violence, domestic, and alcohol consumption, 125  
Visine eye drops, as adulterant, 42, 43  
Vista 1500 analyzer, automated, 417  
Vitamin K, 161  
daily requirement for, 171  
in superwarfarin poisoning, 174  
vegetables rich in, 171, 172  
Vitamin K epoxide reductase complex 1 (VKORC1), 161, 163, 164, 396
Vitos acetaminophen method, 229
Volatile
commonly abused, 114, 115
and GABA receptors, 116
Volume of distribution, 388
Voriconazole, interaction of St. John’s wort with

Warfarin (Coumadin), viii, 161
chromatography of, 174–178, 176, 177
clinically significant interactions with
drugs of, 165–169, 167
in death investigations, 173
direct measurement of, 172–173
electrospray mass spectra of, 176
genotype-guided dosing of, 164
interaction of St. John’s wort with, 364
interactions with dietary supplements/food, 169–172, 170, 172
cranberry juice, 170–171
herbal products, 169–170, 170
interactions with dietary supplements/foods
green tea, 171
vegetables, 171, 172
interaction with common drugs of,
167
intolerance to, 164
properties of, 162
as rat poison, 173
risk of bleeding with, 163–164
superwarfarin poisoning, 173–174
therapeutic drug monitoring of,
162–165
toxicity, 172–173
Warfarin (Coumadin) assay, eQ-PCR
LC, 404
Warfarin poisoning, LC/MS in, 179–180
Warfarin therapy, 162
case report, 163–164
and drug-herb interactions, 359
factors affecting, 172
and influenza vaccine, 168–169
initiating, 163
INR monitoring of, 162–163, 164–165
pharmacogenomics and, 396
Water hemlock (Cicuta maculata), 186, 187
Weight loss products
chromatographic analysis of, 199, 199–201
interference with amphetamine
immunoassays of, 59
Whole blood
for everolimus quantitation, 333
for therapeutic drug monitoring, 326
for therapeutic monitoring
of cyclosporine, 326
of tacrolimus, 331
Widmark formula, 127–128
Wild bean (Phaseolus), 186
Window of detection, 22
Wisconsin Alumni Research Foundation, 162
Women, alcohol metabolized by, 123
Workers Protection Standard for Agricultural Pesticides, 140
Workplace drug testing, 22, 32
challenges for, 32
cut-off concentrations for, 33, 33
legal consequences of, 31
limitations of, 35
medical vs., 34, 34–35
positive, 80
tampering with urine specimens for,
40
THC results in, 71
World Health Organization (WHO), 124
Yew (Taxus baccata), 186
Yohimbe bark, diagnosis of poisoning
with, 205–206
Zinc sulfate, in LC/MS procedures, 346
Zonisamide, 285, 286